A double blind, double dummy, randomised, multi-centre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients with type 2 diabetes fasting during Ramadan
Phase of Trial: Phase IV
Latest Information Update: 03 Jul 2019
At a glance
- Drugs Vildagliptin (Primary) ; Gliclazide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms RAMADAN; STEADFAST
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Feb 2013 New source identified and integrated (United Kingdom Clinical Research Network, 13432).